INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,714,525 | -41.1% | 397,668 | -28.4% | 0.00% | -50.0% |
| Q2 2023 | $35,150,134 | +130.9% | 555,119 | +97.5% | 0.00% | +100.0% |
| Q1 2023 | $15,223,080 | +63.1% | 281,128 | +59.4% | 0.00% | +100.0% |
| Q4 2022 | $9,335,617 | +16.5% | 176,410 | +2.5% | 0.00% | 0.0% |
| Q3 2022 | $8,010,000 | -24.4% | 172,185 | -7.3% | 0.00% | 0.0% |
| Q2 2022 | $10,602,000 | -8.1% | 185,740 | -1.5% | 0.00% | 0.0% |
| Q1 2022 | $11,537,000 | +83.0% | 188,560 | +56.5% | 0.00% | 0.0% |
| Q4 2021 | $6,305,000 | +104.2% | 120,448 | +45.5% | 0.00% | – |
| Q3 2021 | $3,087,000 | -13.1% | 82,804 | -4.9% | 0.00% | – |
| Q2 2021 | $3,551,000 | -52.9% | 87,030 | -60.9% | 0.00% | -100.0% |
| Q1 2021 | $7,542,000 | +50.2% | 222,308 | +40.8% | 0.00% | 0.0% |
| Q4 2020 | $5,022,000 | +169.4% | 157,915 | +117.5% | 0.00% | – |
| Q3 2020 | $1,864,000 | +7.7% | 72,593 | +7.7% | 0.00% | – |
| Q2 2020 | $1,731,000 | +19.5% | 67,430 | -28.4% | 0.00% | – |
| Q1 2020 | $1,448,000 | -66.4% | 94,222 | -25.1% | 0.00% | – |
| Q4 2019 | $4,314,000 | +247.1% | 125,749 | -24.4% | 0.00% | – |
| Q3 2019 | $1,243,000 | -20.1% | 166,336 | +38.7% | 0.00% | – |
| Q2 2019 | $1,556,000 | +6.3% | 119,887 | -0.2% | 0.00% | – |
| Q1 2019 | $1,464,000 | -81.9% | 120,168 | -83.1% | 0.00% | -100.0% |
| Q4 2018 | $8,082,000 | -65.8% | 709,603 | -34.8% | 0.00% | -75.0% |
| Q3 2018 | $23,618,000 | +33.2% | 1,088,421 | +8.5% | 0.00% | 0.0% |
| Q2 2018 | $17,731,000 | -8.8% | 1,003,468 | +8.7% | 0.00% | +33.3% |
| Q1 2018 | $19,434,000 | +61.8% | 923,216 | +11.3% | 0.00% | +50.0% |
| Q4 2017 | $12,011,000 | -5.5% | 829,500 | +2.9% | 0.00% | 0.0% |
| Q3 2017 | $12,716,000 | +9.9% | 805,834 | -13.5% | 0.00% | 0.0% |
| Q2 2017 | $11,569,000 | +7268.8% | 931,497 | +9542.8% | 0.00% | – |
| Q1 2017 | $157,000 | +65.3% | 9,660 | +53.4% | 0.00% | – |
| Q4 2016 | $95,000 | -92.8% | 6,297 | -92.7% | 0.00% | – |
| Q3 2016 | $1,318,000 | +1547.5% | 86,442 | +4075.9% | 0.00% | – |
| Q2 2016 | $80,000 | +247.8% | 2,070 | +154.6% | 0.00% | – |
| Q1 2016 | $23,000 | -63.5% | 813 | -30.2% | 0.00% | – |
| Q4 2015 | $63,000 | +320.0% | 1,164 | +205.5% | 0.00% | – |
| Q3 2015 | $15,000 | -96.0% | 381 | -96.7% | 0.00% | – |
| Q2 2015 | $371,000 | +18450.0% | 11,626 | +6468.4% | 0.00% | – |
| Q3 2014 | $2,000 | -97.3% | 177 | -96.0% | 0.00% | – |
| Q2 2014 | $74,000 | – | 4,396 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |